Skip to main content
News & Announcements

Quotient Sciences and Ensysce Biosciences Continue Collaboration on PF614-MPAR-102

Ensysce Biosciences and Quotient Sciences logos

Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical stage pharmaceutical company developing innovative solutions for pain relief that reduce the potential for opioid abuse and overdose, recently announced the renewal of its collaboration with Quotient Sciences to undertake the study PF614-MPAR-102 to examine and evaluate the full commercial dose range of the PF614-MPAR drug product.

The Phase 1b study, PF614-MPAR-102, will evaluate opioid release following administration of PF614-MPAR at ascending doses. Quotient Sciences' Translational Pharmaceutics® platform for drug development will be again used to manufacture and test the PF614-MPAR drug product, providing expedited clinical study progress.

Read the announcement on Ensysce's website

Read the Ensysce Biosciences case study

Get in touch
Humanity can't afford to wait, so neither can we.